These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7665722)

  • 41. Diltiazem treatment impairs hepatic drug oxidation: studies of antipyrine.
    Carrum G; Egan JM; Abernethy DR
    Clin Pharmacol Ther; 1986 Aug; 40(2):140-3. PubMed ID: 3731677
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Biotransformation of phenazone and sulfadimidine as markers of liver metabolism of drug and xenobiotic oxidation and acetylation in women with breast cancer].
    Orzechowska-Juzwenko K; Wiela-Hojeńska A; Milejski P; Cieślińska A; Hudziec P; Adamska M
    Przegl Lek; 1997; 54(2):103-6. PubMed ID: 9198818
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases.
    Couet C; Brissot P; Messner M; Delamaire D; Gie S; Bourel M
    Ann Gastroenterol Hepatol (Paris); 1984; 20(1):1-6. PubMed ID: 6529154
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of velnacrine on the mixed function oxidase system.
    Eccles MJ; Danbury TC; Ford JM; Roberts CJ
    Eur J Drug Metab Pharmacokinet; 1997; 22(2):121-5. PubMed ID: 9248779
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism].
    Furet Y; Bechtel Y; Le Guellec C; Bechtel PR; Autret-Leca E; Paintaud G
    Therapie; 2002; 57(5):427-31. PubMed ID: 12611196
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pulmonary disease and antipyrine clearance.
    Laybourn C; Tønnesen P; Loft S; Sonne J; Døssing M
    Clin Pharmacol Ther; 1986 Oct; 40(4):415-9. PubMed ID: 3489577
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antipyrine metabolism in acute hepatic porphyria in relapse and remission.
    Birnie GG; McColl KE; Thompson GG; Moore MR; Goldberg A; Brodie MJ
    Br J Clin Pharmacol; 1987 Mar; 23(3):358-61. PubMed ID: 3567053
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
    Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
    Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of chloroquine and primaquine on antipyrine metabolism.
    Back DJ; Purba HS; Park BK; Ward SA; Orme ML
    Br J Clin Pharmacol; 1983 Nov; 16(5):497-502. PubMed ID: 6639836
    [TBL] [Abstract][Full Text] [Related]  

  • 50. N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects.
    Brocvielle H; Muret P; Goydadin AC; Boone P; Broly F; Kantelip JP; Humbert P
    Skin Pharmacol Appl Skin Physiol; 2003; 16(6):386-92. PubMed ID: 14528063
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Physical exercise and improvement of liver oxidative metabolism in the elderly.
    Mauriz JL; Tabernero B; García-López J; Jorquera F; Villa JG; González-Gallego J
    Eur J Appl Physiol; 2000 Jan; 81(1-2):62-6. PubMed ID: 10552268
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antipyrine clearance and metabolite formation in primary biliary cirrhosis.
    Jorquera F; Almar M; Linares A; Olcóz JL; Rodrigo L; González-Gallego J
    Dig Dis Sci; 2001 Feb; 46(2):352-9. PubMed ID: 11281185
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases.
    Kawasaki S; Sugiyama Y; Iga T; Hanano M; Beppu T; Sugiura M; Sanjo K; Idezuki Y
    Clin Pharmacol Ther; 1988 Aug; 44(2):217-24. PubMed ID: 3396264
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of age and sex on metabolism and urinary excretion of antipyrine.
    Jorquera F; Almar M; Pozuelo M; Sansegundo D; González-Sastre M; González-Gallego J
    J Gerontol A Biol Sci Med Sci; 1998 Jan; 53(1):M14-9. PubMed ID: 9467428
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins.
    Penno MB; Dvorchik BH; Vesell ES
    Proc Natl Acad Sci U S A; 1981 Aug; 78(8):5193-6. PubMed ID: 6946467
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.
    Bach D; Blevins R; Kerner N; Rubenfire M; Edwards DJ
    Br J Clin Pharmacol; 1986 Jun; 21(6):655-9. PubMed ID: 3741715
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A population and family study of N-acetyltransferase using caffeine urinary metabolites.
    Bechtel YC; Bonaiti-Pellie C; Poisson N; Magnette J; Bechtel PR
    Clin Pharmacol Ther; 1993 Aug; 54(2):134-41. PubMed ID: 8354022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of arylamine acetyltransferase in the rabbit eye.
    Campbell DA; Schoenwald RD; Duffel MW; Barfknecht CF
    Invest Ophthalmol Vis Sci; 1991 Jul; 32(8):2190-200. PubMed ID: 2071333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential induction of antipyrine metabolism by rifampicin.
    Toverud EL; Boobis AR; Brodie MJ; Murray S; Bennett PN; Whitmarsh V; Davies DS
    Eur J Clin Pharmacol; 1981; 21(2):155-60. PubMed ID: 7341283
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.
    Homeida M; Roberts CJ; Halliwell M; Read AE; Branch RA
    Gut; 1979 Jul; 20(7):596-601. PubMed ID: 488757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.